Dr. Pooja Sethi, MD
Claim this profileTexas Tech University Health Sciences Center (TTUHSC)
Studies Heart Failure
Studies Diastolic Dysfunction
2 reported clinical trials
1 drug studied
Affiliated Hospitals
Clinical Trials Pooja Sethi, MD is currently running
Sulforaphane
for Heart Failure
This trial tests if a broccoli extract called Sulforaphane can help older adults with a certain type of heart failure. The extract may protect the heart by reducing damage and inflammation. Sulforaphane is a compound derived from vegetables like broccoli, known for its anti-inflammatory and antioxidant properties.
Recruiting0 awards Phase 1 & 24 criteria
Sulforaphane
for Chemotherapy-Related Cardiotoxicity
Cardiomyopathy is a major complication of doxorubicin (DOX) chemotherapy, and 10-21% of breast cancer patients receiving DOX experience compromised cardiac function. Recent advancements have increased cancer survivorship but it remains clinically challenging to mitigate the cardiotoxic side effects. Although there are several strategies used to reduce the occurrence and severity of DOX-induced cardiotoxicity, they are not particularly effective. Hence, there is an urgent need to develop new strategies that prevent the cardiotoxic effects of DOX but maintain its potency as a cancer therapy. Because the cellular events responsible for the antitumor activity of DOX and DOX-induced cardiotoxicity are distinctly different, it may be possible to develop therapies that selectively mitigate DOX-induced cardiotoxicity. Thus, the investigators propose to test an adjuvant therapy that combines the phytochemical sulforaphane (SFN) with DOX to attenuate DOX-induced cardiomyopathy. SFN activates the transcription factor Nrf2 and induces defense mechanisms in normal cells. Furthermore, SFN inhibits carcinogenesis and metastases and enhances cancer cell sensitivity to DOX, seemingly through Nrf2-independent mechanisms. SFN has also been tested in several clinical trials, although never together with DOX. Our early animal studies suggest that by activating Nrf2, SFN selectively protects the mouse and rat from DOX cardiotoxicity, enhances survival and enhances the effects of DOX on cancer growth in a rat breast cancer model. The investigators suspect that SFN affects DOX metabolism in cancer cells to enhance tumor regression, or it may synergistically activate other key antitumor mechanisms. Hence, SFN may improve the clinical outcome of cancer therapy by (1) attenuating DOX cardiotoxicity and (2) enhancing the effects of cancer treatment on the tumor. Our hypothesis is that SFN protects the heart from DOX-mediated cardiac injury without altering the antitumor efficacy of DOX. In Aim 1, the investigators will conduct an early-phase clinical trial to determine if SFN is safe to administer to breast cancer patients undergoing DOX chemotherapy. In Aim 2, the investigators will determine if SFN decreases DOX-induced inflammatory responses and enhances Nrf2- and SIRT1-target gene expression in breast cancer patients. Notably, transcript and protein signatures in peripheral blood mononuclear cells (PBMCs) can predict cardiac function in patients undergoing DOX chemotherapy for breast cancer. The investigators will also determine if SFN/DOX treatment activates Nrf2- and SIRT1-dependent gene expression, alters the levels of biomarkers for presymptomatic DOX-cardiotoxicity and mitigates the generation of cardiotoxic metabolites in PBMCs and plasma. These studies will facilitate the development of SFN co-treatment as a strategy to enhance the efficacy and safety of DOX cancer therapy.
Recruiting0 awards Phase 1 & 26 criteria
More about Pooja Sethi, MD
Clinical Trial Related3 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Pooja Sethi, MD has experience with
- Sulforaphane
Breakdown of trials Pooja Sethi, MD has run
Heart Failure
Diastolic Dysfunction
Cardiotoxicity
Cardiomyopathy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Pooja Sethi, MD specialize in?
Pooja Sethi, MD focuses on Heart Failure and Diastolic Dysfunction. In particular, much of their work with Heart Failure has involved treating patients, or patients who are undergoing treatment.
Is Pooja Sethi, MD currently recruiting for clinical trials?
Yes, Pooja Sethi, MD is currently recruiting for 2 clinical trials in Lubbock Texas. If you're interested in participating, you should apply.
Are there any treatments that Pooja Sethi, MD has studied deeply?
Yes, Pooja Sethi, MD has studied treatments such as Sulforaphane.
What is the best way to schedule an appointment with Pooja Sethi, MD?
Apply for one of the trials that Pooja Sethi, MD is conducting.
What is the office address of Pooja Sethi, MD?
The office of Pooja Sethi, MD is located at: Texas Tech University Health Sciences Center (TTUHSC), Lubbock, Texas 79430 United States. This is the address for their practice at the Texas Tech University Health Sciences Center (TTUHSC).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.